Literature DB >> 15358638

Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.

Munir M Zaman1, Andres Gelrud, Omer Junaidi, Meredith M Regan, Michel Warny, Julie C Shea, Ciaran Kelly, Brian P O'Sullivan, Steven D Freedman.   

Abstract

Patients with cystic fibrosis (CF) exhibit an excessive host inflammatory response. The aim of this study was to determine (i) whether interleukin 8 (IL-8) secretion is increased from monocytes from subjects heterozygous as well as homozygous for cystic fibrosis transmembrane conductance regulator (CFTR) mutations and (ii) whether this is due to increased cell surface lipopolysaccharide (LPS) receptors or, alternatively, increased activation of mitogen-activated protein kinases (MAPK). The basal level of IL-8 secretion was higher from monocytes from CF patients than from monocytes from healthy controls (P = 0.02) and obligate heterozygotes (parents of the CF patients). The 50% effective concentrations for LPS-induced IL-8 production for monocytes from both CF patients and obligate heterozygotes were 100-fold lower than those for monocytes from healthy controls (P < 0.05). No differences in the levels of IL-1beta production were seen between these groups. Expression of the LPS surface receptors CD14 and Toll-like receptor 4 were not different between CF patients and healthy controls. In contrast, phosphorylation of the MAPKs p38 and ERK occurred at lower doses of LPS in monocytes from patients heterozygous and homozygous for CFTR mutations. These results indicate that a single allelic CFTR mutation is sufficient to augment IL-8 secretion in response to LPS. This is not a result of increased LPS receptor expression but, rather, is associated with alterations in MAPK signaling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15358638      PMCID: PMC515258          DOI: 10.1128/CDLI.11.5.819-824.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  28 in total

1.  Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients.

Authors:  M S Muhlebach; P W Stewart; M W Leigh; T L Noah
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

2.  Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro.

Authors:  O Tabary; J M Zahm; J Hinnrasky; J P Couetil; P Cornillet; M Guenounou; D Gaillard; E Puchelle; J Jacquot
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

3.  IL-8 release and neutrophil activation by Clostridium difficile toxin-exposed human monocytes.

Authors:  J K Linevsky; C Pothoulakis; S Keates; M Warny; A C Keates; J T Lamont; C P Kelly
Journal:  Am J Physiol       Date:  1997-12

4.  Altered cytokine production by cystic fibrosis tracheal gland serous cells.

Authors:  W Kammouni; C Figarella; S Marchand; M Merten
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

5.  Mutations of the cystic fibrosis gene in patients with chronic pancreatitis.

Authors:  N Sharer; M Schwarz; G Malone; A Howarth; J Painter; M Super; J Braganza
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

6.  Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis.

Authors:  J A Cohn; K J Friedman; P G Noone; M R Knowles; L M Silverman; P S Jowell
Journal:  N Engl J Med       Date:  1998-09-03       Impact factor: 91.245

7.  Early pulmonary inflammation in infants with cystic fibrosis.

Authors:  T Z Khan; J S Wagener; T Bost; J Martinez; F J Accurso; D W Riches
Journal:  Am J Respir Crit Care Med       Date:  1995-04       Impact factor: 21.405

8.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

9.  Activation of NF-kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis respiratory epithelial cells.

Authors:  E DiMango; A J Ratner; R Bryan; S Tabibi; A Prince
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

10.  Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa.

Authors:  A Heeckeren; R Walenga; M W Konstan; T Bonfield; P B Davis; T Ferkol
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

View more
  33 in total

Review 1.  Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.

Authors:  C N Belcher; N Vij
Journal:  Curr Mol Med       Date:  2010-02       Impact factor: 2.222

2.  Cystic Fibrosis Plasma Blunts the Immune Response to Bacterial Infection.

Authors:  Xi Zhang; Amy Pan; Shuang Jia; Justin E Ideozu; Katherine Woods; Kathleen Murkowski; Martin J Hessner; Pippa M Simpson; Hara Levy
Journal:  Am J Respir Cell Mol Biol       Date:  2019-09       Impact factor: 6.914

3.  Inhibition of acinar apoptosis occurs during acute pancreatitis in the human homologue DeltaF508 cystic fibrosis mouse.

Authors:  Matthew J DiMagno; Sae-Hong Lee; Chung Owyang; Shi-yi Zhou
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-06-03       Impact factor: 4.052

4.  Inhibition of p38 mitogen activated protein kinase controls airway inflammation in cystic fibrosis.

Authors:  V Raia; L Maiuri; C Ciacci; I Ricciardelli; L Vacca; S Auricchio; M Cimmino; M Cavaliere; M Nardone; A Cesaro; J Malcolm; S Quaratino; M Londei
Journal:  Thorax       Date:  2005-06-30       Impact factor: 9.139

5.  The NF-kappaB signaling in cystic fibrosis lung disease: pathophysiology and therapeutic potential.

Authors:  Manish Bodas; Neeraj Vij
Journal:  Discov Med       Date:  2010-04       Impact factor: 2.970

6.  The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.

Authors:  C R Martin; P G Blanco; J C Keach; J L Petz; M M Zaman; K R Bhaskar; J E Cluette-Brown; S Gautam; S Sheth; N H Afdhal; K D Lindor; S D Freedman
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

7.  Linoleic acid supplementation results in increased arachidonic acid and eicosanoid production in CF airway cells and in cftr-/- transgenic mice.

Authors:  Munir M Zaman; Camilia R Martin; Charlotte Andersson; Abdul Q Bhutta; Joanne E Cluette-Brown; Michael Laposata; Steven D Freedman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-07-23       Impact factor: 5.464

8.  Subacute TGFβ expression drives inflammation, goblet cell hyperplasia, and pulmonary function abnormalities in mice with effects dependent on CFTR function.

Authors:  Elizabeth L Kramer; William D Hardie; Satish K Madala; Cynthia Davidson; John P Clancy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

9.  Proinflammatory phenotype and increased caveolin-1 in alveolar macrophages with silenced CFTR mRNA.

Authors:  Yaqin Xu; Anja Krause; Hiroko Hamai; Ben-Gary Harvey; Tilla S Worgall; Stefan Worgall
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

10.  CFTR is a negative regulator of NFkappaB mediated innate immune response.

Authors:  Neeraj Vij; Steven Mazur; Pamela L Zeitlin
Journal:  PLoS One       Date:  2009-02-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.